

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>WALTON ALAN G</u> (Last) (First) (Middle) <u>315 POST ROAD WEST</u> (Street) <u>WESTPORT CT 06880</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/26/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ACAD]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series F Convertible Preferred Stock	(2)	(1)	Common Stock	2,291,667	(3)	I	By Oxford Bioscience Partners IV L.P. ⁽⁴⁾
Series F Convertible Preferred Stock	(2)	(1)	Common Stock	23,148 ⁽⁵⁾	(3)	I	By mRNA Fund II, L.P. ⁽⁵⁾
Stock Option (Right to Buy)	06/07/2004	06/13/2013	Common Stock	4,500	1.08	D	

Explanation of Responses:

1. These securities are preferred stock of the issuer and do not have an expiration date.

2. Immediately

3. 1-for-1

4. Securities held of record by Oxford Bioscience Partners IV L.P. ("OBP IV"). Dr. Walton, as an individual general partner of OBP Management IV L.P., the sole general partner of OBP IV may be deemed to beneficially own the shares held of record by OBP IV. Dr. Walton disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

5. Securities held of record by mRNA Fund II L.P. ("mRNA"). Dr. Walton, as an individual general partner of OBP Management IV L.P., the sole general partner of mRNA, may be deemed to beneficially own the shares held of record by mRNA. Dr. Walton disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

Alan G. Walton

05/26/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.